These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 12364842)

  • 1. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial.
    Emslie GJ; Heiligenstein JH; Wagner KD; Hoog SL; Ernest DE; Brown E; Nilsson M; Jacobson JG
    J Am Acad Child Adolesc Psychiatry; 2002 Oct; 41(10):1205-15. PubMed ID: 12364842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study.
    Findling RL; DelBello MP; Zuddas A; Emslie GJ; Ettrup A; Petersen ML; Schmidt SN; Rosen M
    J Am Acad Child Adolesc Psychiatry; 2022 Sep; 61(9):1106-1118.e2. PubMed ID: 35033635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder.
    Emslie GJ; Prakash A; Zhang Q; Pangallo BA; Bangs ME; March JS
    J Child Adolesc Psychopharmacol; 2014 May; 24(4):170-9. PubMed ID: 24815533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder.
    Atkinson SD; Prakash A; Zhang Q; Pangallo BA; Bangs ME; Emslie GJ; March JS
    J Child Adolesc Psychopharmacol; 2014 May; 24(4):180-9. PubMed ID: 24813026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Randomized, Double-Blind, Placebo-Controlled Trial of Vilazodone in Children and Adolescents with Major Depressive Disorder with Twenty-Six-Week Open-Label Follow-Up.
    Findling RL; McCusker E; Strawn JR
    J Child Adolesc Psychopharmacol; 2020 Jul; 30(6):355-365. PubMed ID: 32460523
    [No Abstract]   [Full Text] [Related]  

  • 6. Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study.
    Emslie GJ; Heiligenstein JH; Hoog SL; Wagner KD; Findling RL; McCracken JT; Nilsson ME; Jacobson JG
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1397-405. PubMed ID: 15502599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression.
    Emslie GJ; Rush AJ; Weinberg WA; Kowatch RA; Hughes CW; Carmody T; Rintelmann J
    Arch Gen Psychiatry; 1997 Nov; 54(11):1031-7. PubMed ID: 9366660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder.
    Weihs KL; Murphy W; Abbas R; Chiles D; England RD; Ramaker S; Wajsbrot DB
    J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):36-46. PubMed ID: 29189044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder.
    Judd LL; Rapaport MH; Yonkers KA; Rush AJ; Frank E; Thase ME; Kupfer DJ; Plewes JM; Schettler PJ; Tollefson G
    Am J Psychiatry; 2004 Oct; 161(10):1864-71. PubMed ID: 15465984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes.
    Barbosa L; Berk M; Vorster M
    J Clin Psychiatry; 2003 Apr; 64(4):403-7. PubMed ID: 12716240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Vilazodone in Adolescents with Major Depressive Disorder.
    Durgam S; Chen C; Migliore R; Prakash C; Edwards J; Findling RL
    Paediatr Drugs; 2018 Aug; 20(4):353-363. PubMed ID: 29633166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes.
    March JS; Silva S; Petrycki S; Curry J; Wells K; Fairbank J; Burns B; Domino M; McNulty S; Vitiello B; Severe J
    Arch Gen Psychiatry; 2007 Oct; 64(10):1132-43. PubMed ID: 17909125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial.
    Geller DA; Hoog SL; Heiligenstein JH; Ricardi RK; Tamura R; Kluszynski S; Jacobson JG;
    J Am Acad Child Adolesc Psychiatry; 2001 Jul; 40(7):773-9. PubMed ID: 11437015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study.
    Robinson RG; Schultz SK; Castillo C; Kopel T; Kosier JT; Newman RM; Curdue K; Petracca G; Starkstein SE
    Am J Psychiatry; 2000 Mar; 157(3):351-9. PubMed ID: 10698809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Can-SAD study: a randomized controlled trial of the effectiveness of light therapy and fluoxetine in patients with winter seasonal affective disorder.
    Lam RW; Levitt AJ; Levitan RD; Enns MW; Morehouse R; Michalak EE; Tam EM
    Am J Psychiatry; 2006 May; 163(5):805-12. PubMed ID: 16648320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents.
    Emslie GJ; Kennard BD; Mayes TL; Nightingale-Teresi J; Carmody T; Hughes CW; Rush AJ; Tao R; Rintelmann JW
    Am J Psychiatry; 2008 Apr; 165(4):459-67. PubMed ID: 18281410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
    March J; Silva S; Petrycki S; Curry J; Wells K; Fairbank J; Burns B; Domino M; McNulty S; Vitiello B; Severe J;
    JAMA; 2004 Aug; 292(7):807-20. PubMed ID: 15315995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study.
    Appelberg BG; Syvälahti EK; Koskinen TE; Mehtonen OP; Muhonen TT; Naukkarinen HH
    J Clin Psychiatry; 2001 Jun; 62(6):448-52. PubMed ID: 11465522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symptom clusters in adolescent depression and differential response to treatment: a secondary analysis of the Treatment for Adolescents with Depression Study randomised trial.
    Bondar J; Caye A; Chekroud AM; Kieling C
    Lancet Psychiatry; 2020 Apr; 7(4):337-343. PubMed ID: 32199509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)].
    Hjalmarsson L; Corcos M; Jeammet P
    Encephale; 2005; 31(3):309-16. PubMed ID: 16142045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.